COSCIENS Biopharma Inc
TSX:CSCI
COSCIENS Biopharma Inc
Free Cash Flow
COSCIENS Biopharma Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
COSCIENS Biopharma Inc
TSX:CSCI
|
Free Cash Flow
-$13.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
8%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Free Cash Flow
-CA$1.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
-113%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Free Cash Flow
-$3.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-23%
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Free Cash Flow
$92.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Free Cash Flow
-$233m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-78%
|
CAGR 10-Years
-45%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Free Cash Flow
-CA$9.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
COSCIENS Biopharma Inc
Glance View
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
See Also
What is COSCIENS Biopharma Inc's Free Cash Flow?
Free Cash Flow
-13.9m
USD
Based on the financial report for Mar 31, 2025, COSCIENS Biopharma Inc's Free Cash Flow amounts to -13.9m USD.
What is COSCIENS Biopharma Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
8%
Over the last year, the Free Cash Flow growth was 20%. The average annual Free Cash Flow growth rates for COSCIENS Biopharma Inc have been -15% over the past three years , -7% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet